Effect of Tocilizumab on “Ventilator Free Days” Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis

[1] World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 15 October 2020]. World Health Organization (WHO) Coronavirus disease (COVID-19) pandemic https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed 15 October 2020]. Search in Google Scholar

[2] Aletreby WT, Alharthy AM, Faqihi F, Mady AF, Ramadan OE, Huwait BM, et al. Dynamics of SARS CoV-2 outbreak in the Kingdom of Saudi Arabia: A predictive model. Saudi Crit Care J 2020;4:79–83. doi: 10.4103/sccj.sccj_19_20 AletrebyWT AlharthyAM FaqihiF MadyAF RamadanOE HuwaitBM Dynamics of SARS CoV-2 outbreak in the Kingdom of Saudi Arabia: A predictive model Saudi Crit Care J 2020 4 79 83 10.4103/sccj.sccj_19_20 Open DOISearch in Google Scholar

[3] Mady A, Aletreby W, Abdulrahman B, Lhmdi M, Noor AM, Alqahtani SA, Soliman I, Alharthy A, Karakitsos D, Memish ZA. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series. Ann Med Surg (Lond). 2020 Dec;60:417–424. doi: 10.1016/j.amsu.2020.10.061. MadyA AletrebyW AbdulrahmanB LhmdiM NoorAM AlqahtaniSA SolimanI AlharthyA KarakitsosD MemishZA Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series Ann Med Surg (Lond) 2020 Dec 60 417 424 10.1016/j.amsu.2020.10.061 764280833169088 Open DOISearch in Google Scholar

[4] Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 May 5:10.1002/jmv.25964. doi: 10.1002/jmv.25964. AlattarR IbrahimTBH ShaarSH AbdallaS ShukriK DaghfalJN Tocilizumab for the treatment of severe coronavirus disease 2019 J Med Virol 2020 May 5 10.1002/jmv.25964. 10.1002/jmv.25964 726759432369191 Open DOISearch in Google Scholar

[5] Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020 Sep 29;24(1):589. doi: 10.1186/s13054-020-03306-6. MenzellaF FontanaM SalvaraniC MassariM RuggieroP ScelfoC Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation Crit Care 2020 Sep 29 24 1 589 10.1186/s13054-020-03306-6 752325832993751 Open DOISearch in Google Scholar

[6] Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.25948. AzizM FatimaR AssalyR Elevated interleukin-6 and severe COVID-19: a meta-analysis J Med Virol 2020 10.1002/jmv.25948 726738332343429 Open DOISearch in Google Scholar

[7] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. doi: 10.1016/S0140-6736(20)30566-3. ZhouF YuT DuR FanG LiuY LiuZ Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 2020 395 1054 62 10.1016/S0140-6736(20)30566-3 727062732171076 Open DOISearch in Google Scholar

[8] Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 Feb 28;15:700–704. doi: 10.1016/j.jtho.2020.02.010 TianS HuW NiuL LiuH XuH XiaoS-Y Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer J Thorac Oncol 2020 Feb 28 15 700 704 10.1016/j.jtho.2020.02.010 712886632114094 Open DOISearch in Google Scholar

[9] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 Jul;92(7):814–818. doi: 10.1002/jmv.25801. LuoP LiuY QiuL LiuX LiuD LiJ Tocilizumab treatment in COVID-19: A single center experience J Med Virol 2020 Jul 92 7 814 818 10.1002/jmv.25801 726212532253759 Open DOISearch in Google Scholar

[10] Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep;56(3):106103. doi: 10.1016/j.ijantimicag.2020.106103. LanSH LaiCC HuangHT ChangSP LuLC HsuehPR Tocilizumab for severe COVID-19: a systematic review and meta-analysis Int J Antimicrob Agents 2020 Sep 56 3 106103 10.1016/j.ijantimicag.2020.106103 737768532712333 Open DOISearch in Google Scholar

[11] US Food and Drug Administration. ACTEMRA (Tocilizumab) Injection, for Intravenous or Subcutaneous Use. US Food and Drug Administration; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf US Food and Drug Administration ACTEMRA (Tocilizumab) Injection, for Intravenous or Subcutaneous Use US Food and Drug Administration 2017 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf Search in Google Scholar

[12] Schoenfeld DA, Hayden D, Oldmixon C, Ringwood N, Thompson BT. Statistical design and analysis issues for the ARDS Clinical Trials Network: the coordinating center perspective. Clin Invest 2012;2:275–289. doi: 10.4155/CLI.12.14 SchoenfeldDA HaydenD OldmixonC RingwoodN ThompsonBT Statistical design and analysis issues for the ARDS Clinical Trials Network: the coordinating center perspective Clin Invest 2012 2 275 289 10.4155/CLI.12.14 Open DOISearch in Google Scholar

[13] Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest. 1997 Jul;112(1):164–72. doi: 10.1378/chest.112.1.164. BernardGR WheelerAP AronsMM MorrisPE PazHL RussellJA WrightPE A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group Chest 1997 Jul 112 1 164 72 10.1378/chest.112.1.164 9228372 Open DOISearch in Google Scholar

[14] Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019 Oct 1;200(7):828–836. doi: 10.1164/rccm.201810-2050CP. YehyaN HarhayMO CurleyMAQ SchoenfeldDA ReederRW Reappraisal of ventilator-free days in critical care research Am J Respir Crit Care Med 2019 Oct 1 200 7 828 836 10.1164/rccm.201810-2050CP 681244731034248 Open DOISearch in Google Scholar

[15] Aletreby WT, Mumtaz SA, Al Harthy AM, Shahzad SA, Ramadan OE, Mady AF, et al. Outcome of early mobilization of critically ill patients: A propensity score matching trial. J Intensive & Crit Care. 2018, 4(3); 13. doi: 10.21767/2471-8505.100115 AletrebyWT MumtazSA Al HarthyAM ShahzadSA RamadanOE MadyAF Outcome of early mobilization of critically ill patients: A propensity score matching trial J Intensive & Crit Care 2018 4 3 13 10.21767/2471-8505.100115 Open DOISearch in Google Scholar

[16] Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007 Mar 15;165(6):710–8. doi: 10.1093/aje/kwk052. VittinghoffE McCullochCE Relaxing the rule of ten events per variable in logistic and Cox regression Am J Epidemiol 2007 Mar 15 165 6 710 8 10.1093/aje/kwk052 17182981 Open DOISearch in Google Scholar

[17] Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509. doi: 10.1080/01621459.1999.10474144 FineJP GrayRJ A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 1999 94 496 509 10.1080/01621459.1999.10474144 Open DOISearch in Google Scholar

[18] Matthay MA, Brower RG, Carson S, Douglas IS, Eisner M, Hite D, et al.; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo controlled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561–568. doi: 10.1164/rccm.201012-2090OC. MatthayMA BrowerRG CarsonS DouglasIS EisnerM HiteD National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo controlled clinical trial of an aerosolized b2-agonist for treatment of acute lung injury Am J Respir Crit Care Med 2011 184 561 568 10.1164/rccm.201012-2090OC 317554821562125 Open DOISearch in Google Scholar

[19] Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, et al. Lower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO₂ removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 2013;39:847–856. doi: 10.1007/s00134-012-2787-6. BeinT Weber-CarstensS GoldmannA MüllerT StaudingerT BrederlauJ Lower tidal volume strategy (_3 ml/kg) combined with extracorporeal CO₂ removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study Intensive Care Med 2013 39 847 856 10.1007/s00134-012-2787-6 362540823306584 Open DOISearch in Google Scholar

[20] Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378: 809–818. doi: 10.1056/NEJMoa1705716. AnnaneD RenaultA Brun-BuissonC MegarbaneB QuenotJP SiamiS CRICS-TRIGGERSEP Network Hydrocortisone plus fludrocortisone for adults with septic shock N Engl J Med 2018 378 809 818 10.1056/NEJMoa1705716 29490185 Open DOISearch in Google Scholar

[21] Klopfenstein T, Zayet S, Lohse A, Selles P, Zahra H, Kadiane-Oussou NJ, Toko L, et al; HNF Hospital Tocilizumab multidisciplinary team. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients. Int J Infect Dis. 2020 Aug 13;99:491–495. doi: 10.1016/j.ijid.2020.08.024. KlopfensteinT ZayetS LohseA SellesP ZahraH Kadiane-OussouNJ TokoL HNF Hospital Tocilizumab multidisciplinary team Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients Int J Infect Dis 2020 Aug 13 99 491 495 10.1016/j.ijid.2020.08.024 742357432798660 Open DOISearch in Google Scholar

[22] Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020 Oct;2(10):e603–e612. doi: 10.1016/S2665-9913(20)30277-0. BiranN IpA AhnJ GoRC WangS MathuraS Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study Lancet Rheumatol 2020 Oct 2 10 e603 e612 10.1016/S2665-9913(20)30277-0 742830332838323 Open DOISearch in Google Scholar

[23] Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11:ciaa954. doi: 10.1093/cid/ciaa954. SomersEC EschenauerGA TroostJP GolobJL GandhiTN WangL Tocilizumab for treatment of mechanically ventilated patients with COVID-19 Clin Infect Dis 2020 Jul 11 ciaa954 10.1093/cid/ciaa954 745446232651997 Open DOISearch in Google Scholar

[24] Eimer J, Vesterbacka J, Svensson AK, Stojanovic B, Wagrell C, Sönnerborg A, et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study. J Intern Med. 2020 Aug 3:10.1111/joim.13162. doi: 10.1111/joim.13162. EimerJ VesterbackaJ SvenssonAK StojanovicB WagrellC SönnerborgA Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study J Intern Med 2020 Aug 3 10.1111/joim.13162. 10.1111/joim.13162 743641532744399 Open DOISearch in Google Scholar

[25] REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 Feb 25:NEJMoa2100433. doi: 10.1056/NEJMoa2100433. REMAP-CAP Investigators GordonAC MounceyPR Al-BeidhF RowanKM NicholAD ArabiYM AnnaneD BeaneA van Bentum-PuijkW BerryLR BhimaniZ BontenMJM BradburyCA BrunkhorstFM BuzgauA ChengAC DetryMA DuffyEJ EstcourtLJ FitzgeraldM GoossensH HaniffaR HigginsAM HillsTE HorvatCM LamontagneF LawlerPR LeavisHL LinstrumKM LittonE LorenziE MarshallJC MayrFB McAuleyDF McGlothlinA McGuinnessSP McVerryBJ MontgomerySK MorpethSC MurthyS OrrK ParkeRL ParkerJC PatanwalaAE PettiläV RademakerE SantosMS SaundersCT SeymourCW Shankar-HariM SliglWI TurgeonAF TurnerAM van de VeerdonkFL ZarychanskiR GreenC LewisRJ AngusDC McArthurCJ BerryS WebbSA DerdeLPG Interleukin-6 receptor antagonists in critically ill patients with Covid-19 N Engl J Med 2021 Feb 25 NEJMoa2100433. 10.1056/NEJMoa2100433 795346133631065 Open DOISearch in Google Scholar

[26] Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, Machado FR, Lopes RD, Berwanger O, Azevedo LCP, Avezum Á, Lisboa TC, Rojas SSO, Coelho JC, Leite RT, Carvalho JC, Andrade LEC, Sandes AF, Pintão MCT, Castro CG Jr, Santos SV, de Almeida TML, Costa AN, Gebara OCE, de Freitas FGR, Pacheco ES, Machado DJB, Martin J, Conceição FG, Siqueira SRR, Damiani LP, Ishihara LM, Schneider D, de Souza D, Cavalcanti AB, Scheinberg P; Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84. VeigaVC PratsJAGG FariasDLC RosaRG DouradoLK ZampieriFG MachadoFR LopesRD BerwangerO AzevedoLCP AvezumÁ LisboaTC RojasSSO CoelhoJC LeiteRT CarvalhoJC AndradeLEC SandesAF PintãoMCT CastroCGJr SantosSV de AlmeidaTML CostaAN GebaraOCE de FreitasFGR PachecoES MachadoDJB MartinJ ConceiçãoFG SiqueiraSRR DamianiLP IshiharaLM SchneiderD de SouzaD CavalcantiAB ScheinbergP Coalition covid-19 Brazil VI Investigators Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial BMJ 2021 Jan 20 372 n84 10.1136/bmj.n84 781525133472855 Open DOISearch in Google Scholar

[27] Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021 Feb 25:NEJMoa2028700. doi: 10.1056/NEJMoa2028700. RosasIO BräuN WatersM GoRC HunterBD BhaganiS SkiestD AzizMS CooperN DouglasIS SavicS YoungsteinT Del SorboL Cubillo GracianA De La ZerdaDJ UstianowskiA BaoM DimonacoS GrahamE MatharuB SpotswoodH TsaiL MalhotraA Tocilizumab in hospitalized patients with severe Covid-19 pneumonia N Engl J Med 2021 Feb 25 NEJMoa2028700. 10.1056/NEJMoa2028700 795345933631066 Open DOISearch in Google Scholar

[28] Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474–e484. doi: 10.1016/S2665-9913(20)30173-9. GuaraldiG MeschiariM Cozzi-LepriA MilicJ TonelliR MenozziM Tocilizumab in patients with severe COVID-19: a retrospective cohort study Lancet Rheumatol 2020 Aug 2 8 e474 e484 10.1016/S2665-9913(20)30173-9 731445632835257 Open DOISearch in Google Scholar